Announcement on Company Products Being Selected for National Centralized Drug Procurement

Hefei Lifeon Pharmaceutical Co., Ltd.·August 3, 2026·2 pages

✨ AI Summary

Hefei Lifang Pharmaceutical Co., Ltd. announced its products were selected for the 12th batch of national centralized drug procurement. This is expected to expand sales, increase market share, and enhance brand influence, positively impacting future performance. The selection is subject to confirmation after a public notice period.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 003020

Securities Abbreviation: Lifang Pharmaceutical

Announcement No.: 2026-026

Hefei Lifang Pharmaceutical Co., Ltd.

Announcement on Company Products Being Selected for National Centralized Drug Procurement

The Company and all members of the Board of Directors guarantee the content of this information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Recently, Hefei Lifang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Lifang Pharmaceutical") applied for the national centralized drug procurement (12th batch). According to the "Proposed Selection Results Announcement of the 12th Batch of National Centralized Drug Procurement" issued by the National Joint Procurement Office for Drug Centralized Procurement on July 31, 2026, some of the Company's products are proposed to be selected for this centralized procurement. The relevant situation is hereby announced as follows:

I. Basic Information of Proposed Selected Products

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.